MYRIAD GENETICS INC (MYGN) Stock Price, Forecast & Analysis
USA - NASDAQ:MYGN - US62855J1043 - Common Stock
MYGN Key Statistics, Chart & Performance
The current stock price of MYGN is 6.71 USD. In the past month the price decreased by -13.97%. In the past year, price decreased by -56%.
MYGN Latest News, Press Relases and Analysis
MYGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About MYGN
Company Profile
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Company Info
MYRIAD GENETICS INC
322 North 2200 West
Salt Lake City UTAH 84108 US
CEO: R. Bryan Riggsbee
Employees: 2700
Phone: 18015843600
MYRIAD GENETICS INC / MYGN FAQ
What does MYRIAD GENETICS INC do?
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Can you provide the latest stock price for MYRIAD GENETICS INC?
The current stock price of MYGN is 6.71 USD. The price increased by 5.67% in the last trading session.
What is the dividend status of MYRIAD GENETICS INC?
MYGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of MYGN stock?
MYGN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of MYGN stock?
MYRIAD GENETICS INC (MYGN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for MYRIAD GENETICS INC?
The Revenue of MYRIAD GENETICS INC (MYGN) is expected to decline by -2.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for MYGN stock?
You can find the ownership structure of MYRIAD GENETICS INC (MYGN) on the Ownership tab.
MYGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MYGN. When comparing the yearly performance of all stocks, MYGN is a bad performer in the overall market: 84.74% of all stocks are doing better.
MYGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MYGN. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative.
MYGN Financial Highlights
Over the last trailing twelve months MYGN reported a non-GAAP Earnings per Share(EPS) of 0.05. The EPS decreased by -64.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| Debt/Equity | 0.32 |
MYGN Forecast & Estimates
19 analysts have analysed MYGN and the average price target is 7.48 USD. This implies a price increase of 11.47% is expected in the next year compared to the current price of 6.71.
For the next year, analysts expect an EPS growth of -96.38% and a revenue growth -2.05% for MYGN